[14] The latter is particularly relevant, since bladder cancer is the second most prevalent malignancy after prostate cancer in middle-aged and elderly men ... patients with advanced TCC and ...

Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of ...

Historically, chemotherapy using cisplatin has been the standard treatment for advanced bladder ... is the fourth most common among men. Like any other cancer, bladder cancer can spread beyond ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...

The aim of this Review is to critically assess the currently used methods for the treatment of muscle ... In a study by the Advanced Bladder Cancer Meta-analysis Collaboration, the researchers ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...

This option can be used for some patients who are ineligible for bladder removal surgery. Those with advanced or metastatic disease may benefit from chemotherapy and a variety of immunotherapies that ...

Bladder cancer affects over 52,000 men and women in the United States on an annual basis ... Removal of the tumor through a cystoscope frequently is adequate treatment. Over time these tumors have a ...